Date:7/28/2011

oodwill 612.9 402.5 Other intangible assets, net 2,679.4 1,978.9 Deferred tax asset 128.3 110.4 Other non-current assets 48.0 60.5 Total assets 6,165.6 5,387.6 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses 1,317.5 1,239.3 Convertible bonds 1,100.0 - Deferred tax liability 4.4 4.4 Other current liabilities 75.5 49.6 Total current liabilities 2,497.4 1,293.3 Non-current liabilities: Convertible bonds - 1,100.0 Deferred tax liability 579.0 352.1 Other non-current liabilities 173.6 190.8 Total liabilities 3,250.0 2,936.2 Equity: Common stock of 5p par value; 1,000 million shares authorized; and 562.3 million shares issued and outstanding (2010: 1,000 million shares authorized; and 562.2 million shares issued and outstanding) 55.7 55.7 Additional paid-in capital 2,799.6 2,746.4 Treasury stock: 11.5 million shares (2010: 14.0 million) (253.4) (276.1) Accumulated other comprehensive income 204.3 85.7 Retained earnings / (accumulated deficit) 109.4 (160.3) Total equity 2,915.6 2,451.4 Total liabilities and equity 6,165.6 5,387.6

Unaudited US GAAP results for the three months and six months to June 30, 2011
Consolidated Statements of Income

3 months to 3 months to 6 months to 6 months to June 30, June 30, June 30, June 30, 2011 2010 2011 2010 $M $M $M $M Revenues: Product sales 993.3 764.3 1,882.6 1,482.4 Royalties 63.4 82.7 137.0 178.0 Other revenues 6.2 2.4 15.5 5.1 Total revenues 1,062.9 849.4 2,035.1 1,665.5 Costs and expenses: Cost of product sales(1) 143.7 119.1 268.2 221.0 Research and development 176.9 147.0 354.8 278.0 Selling, general and administrative(1) 440.3 354.4 843.2 714.3 Loss/(gain) on sale of product rights 2.2 (4.1) 3.5 (4.1) Reorganization costs 7.5 8.6 13.0 13.6 Integration and acquisition costs 9.0 - 2.6 0.6 Total operating expenses 779.6 625.0 1,485.3 1,223.4 Operating income 283.3 224.4 549.8 442.1 Interest income 0.6 0.5 1.2 0.8 Interest expense (9.9) (8.3) (19.1)
'/>"/>

SOURCE Shire plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related biology technology :

1. Neogen Reports 27% Increase in Quarterly Net Income
2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
3. Microbix Has Best-Ever Quarterly Sales
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Quest Diagnostics Declares Quarterly Cash Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
10. Abbott Declares 343rd Consecutive Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend